2016-2021年国家医保谈判药品可及性研究——基于全国大数据的实证分析

    Research on the Accessibility of National Medical Insurance Negotiation Drugs from 2016 to 2021——An Empirical Analysis Based on the National Big Data

    • 摘要: 目的 调查全国范围内国家医保谈判药品(以下简称"国谈药品")的可及性,为相关部门进一步推动国谈药品的落地提供数据支持。方法 对2016-2021年中国30个省级行政区的1 059家二、三级公立综合医院的国谈药品采购相关数据进行调查分析。结果 2016-2021年国谈药品的可及性整体呈上升趋势;三级公立综合医院国谈药品的可获得率均明显高于二级公立综合医院;2021年国谈药品中西药的平均可获得率明显高于中成药(31.60% vs 17.87%);推行时间较长的国谈药品的可获得率偏高;2021年各省二、三级公立综合医院国谈药品配备率的中位数分别为17.35%和32.93%。结论 国谈药品的可获得率与医疗机构水平、推行落地时间长短、药品适用的疾病谱等因素有关,医疗机构应进一步落实相关政策,保障国谈药品配备。

       

      Abstract: OBJECTIVE To investigate the availability of national medical insurance negotiation drugs(national negotiated drugs) nationwide, and provide data support for relevant departments to further promote the implementation of national negotiated drugs. METHODS The national negotiated drugs were statistically analyzed 1 059 secondary and tertiary public general hospitals in 30 provincial administrative regions of China during 2016-2021. RESULTS From 2016 to 2021, the general trend of the availability of national negotiated drugs was upward and the availability rate of national negotiated drugs in tertiary general hospitals was significantly higher than that in secondary general hospitals. The average availability rate of Western medicines was significantly higher than Chinese patent medicines(31.60% vs 17.87%). In addition, the availability rate of national negotiated drugs that had been implemented for a long time was comparatively high. In 2021, the medians of the average drug allocation rates of secondary and tertiary public general hospitals in the provinces were 17.35% and 32.93%, respectively. CONCLUSION The availability rate of national negotiated drugs is related to factors such as the level of medical institutions, the length of time for implementation, and the spectrum of diseases to which drugs are adapted. Medical institutions should further implement relevant policies to ensure the availability of negotiation drugs.

       

    /

    返回文章
    返回